同期肝移植联合袖状胃切除术可持久减重、改善代谢综合征并减少移植物脂肪变
这项多中心回顾性队列研究比较了因代谢功能障碍相关脂肪性肝病(MASLD)行肝移植的肥胖患者中,同期肝移植联合袖状胃切除术(LTSG,n=72)与单纯肝移植(n=185)的长期结局。LTSG组体重减轻持续超过9年,糖尿病和高血压患病率降低,移植物脂肪变发生率更低,死亡和移植物丢失无显著差异。
要点
- LTSG组体重减轻持续超过9年(p<0.001),单纯肝移植组无显著变化。
- 随访8年后LTSG组糖尿病患病率显著低于单纯肝移植组(p<0.05)。
- LTSG组移植物脂肪变发生率显著低于单纯肝移植组(p=0.004)。
核心结论
- 与单纯肝移植相比,LTSG可实现持久减重、糖尿病和高血压缓解,并减少脂肪变复发及可能的纤维化,且不增加死亡或移植物丢失。
研究设计与样本
- 多中心回顾性队列研究,分析采用单一临床方案行LTSG的患者(n=72)和因MASLD行单纯肝移植且BMI>30的患者(n=185)。
- LTSG组随访4-153个月(中位41个月),单纯肝移植组随访12-161个月(中位75个月)。
主要发现
- LTSG组与单纯肝移植组的死亡率和移植物丢失无显著差异。
- 随访8年后LTSG组糖尿病患病率显著低于单纯肝移植组(p<0.05)。
- LTSG组高血压患病率从61.1%降至35.8%(p<0.01)。
- LTSG组(平均起始BMI 45.5)体重较基线显著减轻持续超过9年(p<0.001),单纯肝移植组(平均起始BMI 34.0)无显著变化。
- LTSG组移植物脂肪变发生率显著低于单纯肝移植组(p=0.004);术后3-10年纤维化患病率在LTSG组降低(相对风险比0.46;p=0.09)。
关键数值与推荐
- LTSG组高血压患病率从61.1%降至35.8%(p<0.01)。
- 术后3-10年纤维化相对风险比0.46(p=0.09)。
- LTSG组严重胃食管反流病发生率为11.1%,危险因素包括既往糖尿病和胃食管反流病。
- LTSG组1例发生胃袖状切除术后漏,1例需行食管裂孔疝修补。
临床怎么用
- 原文结论认为LTSG可实现持久减重、糖尿病和高血压缓解,并减少脂肪变复发及可能的纤维化,且不增加死亡或移植物丢失。
- 原文指出肝移植联合袖状胃切除术可在多个中心成功实施,并为终末期肝病和肥胖提供长期疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The prevalence of obesity and metabolic syndrome is rising among liver transplant (LT) candidates, many of whom have metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to determine the long-term impact of simultaneous LT and sleeve gastrectomy (LTSG) in patients with obesity transplanted for MASLD. METHODS: We analyzed patients undergoing LTSG using a single clinical protocol (n = 72), and patients with BMI >30 who underwent LT alone for MASLD (n = 185) in a multicenter retrospective cohort study. Follow-up duration was 4-153 (median 41) months for LTSG and 12-161 (median 75) months for LT. Outcomes included mortality, graft loss, BMI, metabolic syndrome components, allograft steatosis and fibrosis. RESULTS: Mortality and graft loss were not significantly different between the LT and LTSG groups. The prevalence of diabetes was significantly lower in patients undergoing LTSG vs. LT alone after 8 years of follow-up (p <0.05), while hypertension decreased from 61.1% to 35.8% in the LTSG group (p <0.01). Patients undergoing LTSG (average starting BMI of 45.5) experienced significant weight loss compared to baseline for >9 years (p <0.001), while no significant change was seen for the LT-alone group (average starting BMI 34.0). The incidence of allograft steatosis was significantly lower in the LTSG vs. LT group (p = 0.004). The prevalence of fibrosis was reduced in the LTSG vs. LT group 3-10 years postoperatively (relative risk ratio 0.46; p = 0.09). One patient in the LTSG group had a gastric sleeve leak and one required hiatal hernia repair. Severe gastroesophageal reflux disease occurred in 11.1% of the LTSG group; risk factors included pre-existing diabetes and gastroesophageal reflux disease. CONCLUSIONS: LTSG results in sustained weight loss, resolution of diabetes and hypertension, and reduced recurrence of steatosis and possibly fibrosis compared to LT alone. It confers no increase in mortality or graft loss. IMPACT AND IMPLICATIONS: The optimal approach to liver transplant for patients with obesity and end-stage liver disease remains uncertain, especially given the risk for recurrent metabolic dysfunction-associated steatotic liver disease. The current study provides the first multicenter analysis of outcomes for patients treated with combined liver transplant and sleeve gastrectomy and includes an assessment of key outcomes of interest such as weight loss efficacy, recurrent steatosis and fibrosis, and diabetes, as well as reflux (a known complication of sleeve gastrectomy) in addition to assessing for sarcopenia prior to transplant. The results demonstrate that combined liver transplant and sleeve gastrectomy can be successfully adopted at multiple centers and provides long-term efficacy in managing both end-stage liver disease and obesity, which may be of interest not only for clinicians and researchers, but also for patients and policy makers.
引用
- Larson EL, Ellias SD, Blezek DJ, et al. Simultaneous liver transplant and sleeve gastrectomy provides durable weight loss, improves metabolic syndrome and reduces allograft steatosis. J Hepatol. 2025. PMID: 40089069. doi:10.1016/j.jhep.2025.02.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。